Poïesis is focused on sourcing late-stage or approved products from human R&D and evaluating their viability for in-licensing to develop for the veterinary market
Poïesis has agreed to licensing terms for the worldwide animal IP rights to two innovative nanoparticle drug reformulations to combat systemic fungal infections and to treat dry eye. In initial studies, these novel formulations have shown longer and more robust efficacy, with a significant reduction of undesirable side effects.
We are working closely with the biotechnology companies that are developing these products for use in humans, which allows Poïesis unprecedented access to data and drug product for clinical trials.
We continue to evaluate novel therapeutics that we encounter which may address unmet or poorly served needs in the pet medicines market.